At Which Stage of Gastric Cancer Progression Do Levels of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 Increase? Application in Advanced Gastric Cancer Treatment

Eui Soo Han, Han Hong Lee, Jun Suh Lee, Kyo Young Song, Cho Hyun Park, and Hae Myung Jeon

Division of Gastrointestinal Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea

Purpose: Since there are no proven tumor markers that reflect the course of gastric cancer, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are commonly used alternatives. However, the degree of progression that corresponds to an increase in these markers, and the values of these markers at different cancer stages, remains unclear.

Materials and Methods: This study enrolled 1,733 gastric cancer patients who underwent surgery and whose pre-operative CEA and CA19-9 levels were known. Survival curves and mean values of the two markers were compared according to the degree of cancer progression: serosa-unexposed (SU), serosa-exposed (SE), direct invasion (DI), localized seeding (P1), and extensive seeding (P2).

Results: The 5-year overall survival rates at each stage differed significantly, except between DI and P1 patients (17.1% vs. 10.5%, P=0.344). The mean CEA values in SU, SE, DI, P1, and P2 patients were 5.80, 5.48, 13.36, 8.06, and 22.82, respectively. The CA19-9 values for these patients were 49.40, 38.97, 101.67, 73.77, and 98.57, respectively. The increase in CEA in P2 patients was statistically significant (P=0.002), and the increases in CA19-9 in DI and P2 patients were significant (P=0.025, 0.007, respectively). There was a fair correlation between the two markers in P2 patients (r=0.494, P<0.001).

Conclusions: CA19-9 can be used to assess DI of gastric cancer into adjacent organs. Both markers are useful for predicting the presence of extensive peritoneal seeding.

Key Words: Carcinomatosis; Disease progression; Neoplasm invasiveness; Stomach neoplasms; Tumor markers, biological

Introduction

Tumor markers (TMs) are defined as circulating substances that can be measured quantitatively and that have a causal relationship with malignant neoplasia. Although primary neoplasms are the main sources of TMs, other organs influenced by the cancer may be origin sites for TMs. Since TMs reflect the cellular, biochemical, and genetic alterations caused by cancer, they have clinical value that can be roughly divided into two categories: determination of prognosis and diagnosis of cancer. With regard to prognosis, TMs should reflect the progression of the cancer after initial treatment as well as the response to subsequent treatments with agents such as chemotherapy. For diagnostic utility, TMs must be able to distinguish between benign disease and malignancy. Additionally, TMs may have step-wise threshold values that correlate with cancer stage.

There are currently no specific TMs for gastric cancer. In the absence of an established marker, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are the most commonly used alternatives. Although these two markers are currently widely used to reflect the state of gastric cancer, the specific degree of disease progression that is accompanied by a significant increase...
in CEA and CA19–9 has not been determined. Additionally, values for these two markers at each stage of progression have not been specified. The aim of this study was to determine the stage of progression at which CEA and CA19–9 increase, and to establish values for these markers at each stage.

**Materials and Methods**

1. **Study group**

There were 3,206 gastric cancer patients who underwent surgery at the Uijeongbu and Seoul St. Mary’s Hospitals between 1989 and 2006. After exclusion of patients who received neoadjuvant chemotherapy or who had other organ malignancies, this study included 1,733 patients with pre-operatively measured CEA and CA19–9 values. Demographic data and results of follow-up were obtained retrospectively from the Gastric Cancer Patient Registry of the Uijeongbu and Seoul St. Mary’s Hospitals.

Regular follow-up visits were conducted according to our standard protocol (every 3 and 6 months for advanced and early gastric cancer, respectively, for the first 3 years; every 12 months thereafter), and the mean follow-up period for the 1,733 enrolled patients was 75.6±59.7 months (range, 0.2–259.7 months). Survival rates were repeatedly determined using registration data from the Korea National Statistical Office and medical records.

The Institutional Review Board of the Ethics Committee of the College of Medicine at The Catholic University of Korea approved this study (XC13RIMI0124U).

2. **Classification of progression**

Pathological stages in the present study were reclassified according to the seventh edition of the American Joint Committee on Cancer tumor node metastasis staging system. The degree of cancer progression was categorized into five groups. The serosa-unexposed (SU) group included patients with a T-stage up to T3, meaning their tumors had invaded subserosal tissue. The serosa-exposed (SE) group included patients that were stage T4a, meaning their tumors had invaded the serosa. The direct invasion (DI) group included patients that were stage T4b, indicating their tumors had invaded into adjacent structures. The localized seeding (P1) group included patients with seeding in the greater omentum or the peritoneum above the transverse colon. The extensive seeding (P2) group included patients with seeding in the diaphragm or the peritoneum below the transverse colon.

3. **Statistical analysis**

Differences between groups were analyzed using chi-square tests or Fisher’s exact tests for proportions and analysis of variance with the least significant difference and Tukey’s b test for continuous variables. Survival curves were estimated using the Kaplan–Meier method with a log-rank test for univariate analysis. Pearson correlation coefficients were calculated to assess correlations. Statistical analyses were performed using SPSS software, version 13.0 (SPSS Inc., Chicago, IL, USA). Values of P<0.05 were considered to indicate statistical significance.

| Variable | Value |
|----------|-------|
| Gender   |       |
| Male     | 1,179 |
| Female   | 554   |
| Age in years | 57.7±11.9 (20–91) |
| Histological type |     |
| Papillary | 16    |
| Well     | 266   |
| Moderately | 467  |
| Poorly   | 709   |
| Mucinous | 56    |
| Poorly cohesive | 219  |
| Depth of invasion* | |
| T1       | 714   |
| T2       | 236   |
| T3       | 236   |
| T4a      | 422   |
| T4b      | 125   |
| Lymph node metastasis* | |
| N0       | 896   |
| N1       | 203   |
| N2       | 185   |
| N3       | 449   |
| Distant metastasis* | |
| M0       | 1,558 |
| M1       | 175   |
| Pathological stage* | |
| I        | 877   |
| II       | 209   |
| III      | 472   |
| IV       | 175   |

Table 1. Patient characteristics (n=1,733)

Values are presented as number or mean±standard deviation (range). *Classification according to the standard of the 7th edition of the American Joint Committee on Cancer (AJCC) staging system.
Results

The characteristics of enrolled patients are described in Table 1. In ascending order of progression, there were 1,166 patients (67.3%) in the SU group, 363 (20.9%) in the SE group, 59 (3.4%) in the DI group, 51 (2.9%) in the P1 group, and 94 (5.4%) in the P2 group.

The 5-year survival rates were 88.4% for the SU group, 50.1% for the SE group, 17.1% for the DI group, 10.5% for the P1 group, and 6.7% for the P2 group (Fig. 1). The survival rates for each stage were significantly different, except between the DI and P1 groups (17.1% vs. 10.5%, P=0.344).

The mean CEA value was 5.80±64.0 μg/ml for the SU group, 5.48±16.1 μg/ml for the SE group, 13.36±40.9 μg/ml for the DI group, 8.06±19.3 μg/ml for the P1 group, and 22.82±106.7 μg/ml for the P2 group (Fig. 2). The mean CA19-9 value was 49.40±928.9 U/ml for the SU group, 38.97±129.3 U/ml for the SE group, 101.67±193.2 U/ml for the DI group, 73.77±158.9 U/ml for the P1 group, and 98.57±212.4 U/ml for the P2 group (Fig. 3). The mean values of both markers were not significantly different between the SU and SE groups (CEA: 5.80±64.0 μg/ml vs. 5.48±16.1 μg/ml, P=0.927; CA19-9: 49.40±928.9 U/ml vs. 38.97±129.3 U/ml, P=0.857). CEA levels increased significantly in the P2 group compared to the other groups (P=0.002), and CA19-9 was significantly increased in groups DI and P2 compared to the other groups (P=0.025, 0.007, respectively).

To investigate the relationship between the two markers, CEA and CA19-9 levels were compared in all patients and within each group. CEA and CA19-9 levels were poorly correlated when we analyzed the group of all patients and the SU group (all patients: r=0.065, P=0.025; SU group: r=0.075, P=0.032). There were no correlations between the two markers in the SE, DI, and P1 groups (SE group: r=0.067, P=0.311; DI group: r=−0.081, P=0.633; P1 group: r=0.292, P=0.084). There was a fair correlation between CEA and CA19-9 levels in the P2 group (r=0.494, P<0.001; Fig. 4).

Discussion

CEA is an oncofetal protein involved in cell adhesion and the inhibition of apoptosis. Normal serum CEA levels range from 0.0

Fig. 1. Overall survival rates of the five groups: serosa-unexposed (SU), serosa-exposed (SE), direct invasion (DI), localized seeding (P1), and extensive seeding (P2). SU vs. SE, P<0.001; SE vs. DI, P<0.001; DI vs. P1, P=0.344; P1 vs. P2, P=0.042.

Fig. 2. Comparison of the mean CEA levels among the five groups. The P2 group had a significantly higher CEA value (22.82±106.7 μg/ml; P=0.002). Error bar is ±2 standard error. CEA = carcinoembryonic antigen; SU = serosa-unexposed; SE = serosa-exposed; DI = direct invasion; P1 = localized seeding; P2 = extensive seeding.

Fig. 3. Comparison of the mean CA19-9 levels among the five groups. The DI and P2 groups had significantly higher CA19-9 values (DI, 101.67±193.2 U/ml, P=0.025; P2, 98.57±212.4 U/ml, P=0.007). Error bar is ±2 standard error. CA19-9 = carbohydrate antigen 19-9; SU = serosa-unexposed; SE = serosa-exposed; DI = direct invasion; P1 = localized seeding; P2 = extensive seeding.
Conditions such as inflammatory bowel disease, pancreatitis, liver cirrhosis, and chronic obstructive pulmonary disease can cause borderline CEA elevation, resulting in levels from 2.5 to 5.0 μg/ml. For cancer, the main clinical use of CEA is in colorectal cancer patients. \[11-13\] CA19-9 is a mucin-type glycoprotein that has a normal range of up to 37 U/ml. The main clinical use of CA19-9 is in pancreatic cancer patients. CA19-9 is also elevated in conditions such as benign biliary tract disease and pancreatitis. \[14-16\] These markers can be readily analyzed using blood samples and relatively inexpensive methods.

As mentioned above, CEA and CA19–9 are used as alternative TMs in gastric cancer, and many studies have reported that these markers have clinical value in gastric cancer.\[6,8,17\] These markers have little value as screening tools or as diagnostic markers. However, the levels of both CEA and CA19–9 correlate with tumor burden, so the degree of elevation of these markers reflects cancer progression. Thus, these markers are most commonly used to monitor cancer growth and response to therapy. Although CEA and CA19–9 are relatively inaccurate in early disease, the levels of the markers correlate with advanced stages of cancer progression.\[7\]

Tumor burden increases through the sequence of cancer progression, so TM levels also increase. There are two distinct modes of progression in gastric cancer: local invasion and peritoneal seeding.\[18,19\] In some cases, local invasion is advanced, but there is no peritoneal dissemination. In contrast, some cases show peritoneal dissemination with no local invasion. In the present study, gastric cancer patients were categorized into five groups according to tumor burden: (1) SU group, marginal tumor burden; (2) SE group, minor tumor burden; (3) DI group, one subtype of major tumor burden; (4) P1 and P2 groups, other subtypes of major tumor burden. For both markers, levels did not correlate with serosal exposure of the tumor. However, marker levels were significantly higher in the P2 group. Additionally, CA19–9 had a peak average level of 101.67 U/ml in the DI group, which was significantly higher than the other groups, with the exception of the P2 group. These results indicate that CEA and CA19–9 are useful for prediction of extensive peritoneal seeding, not localized carcinomatosis. Additionally, CA19–9 is valuable for assessing local invasion of gastric cancer.

Radiological evaluation sometimes has limited value in preoperative staging, even in very advanced gastric cancer where there is suspicion of DI or peritoneal seeding.\[20,21\] In such cases, a staging laparoscopy is recommended to determine a more accurate diagnosis and to decide the therapeutic plan.\[21\] However, a staging
laparoscopy is an invasive procedure that requires general anesthesia. The findings of this study can be used to predict cancer progression in cases where the condition of the patient makes a staging laparoscopy infeasible. For instance, some advanced gastric cancer cases have ambiguous radiological findings, such as a small amount of ascites or a blurred border between the stomach and an adjacent organ. If patients in these cases have increased levels of CEA and CA19–9, this information could help doctors choose a treatment plan, such as palliative treatment or neoadjuvant chemotherapy.

We conducted a correlation analysis to evaluate the clinical application of the combination of the two markers in gastric cancer patients. There was a fair correlation between the two markers in the P2 group; therefore, a combined increase in both markers would be expected to predict extensive peritoneal seeding. Insufficient correlations were found between the markers in the SE, DI, and P1 groups. Among these groups, only the DI group had a tendency towards an inverse relationship between the levels of the two markers. This result indicates that increased CA19–9 alone suggests adjacent organ invasion by the gastric cancer.

A drawback of the present study was the lack of a cut-off value. Although the mean values for CEA in the P2 group and for CA19–9 in the DI and P2 groups were significantly higher than the values for the other stages, receiver operating characteristic curve analysis did not identify cut-off values for the two markers in the DI and P2 groups (data not shown). These results may have been obtained because of the low organ specificity of these markers, or because of the wide variation in their levels (as indicated by the standard deviations).

In conclusion, CEA and CA19–9 levels are useful for predicting the presence of extensive peritoneal seeding, but not P1. Additionally, CA19–9 can be used to assess DI of adjacent organs by gastric cancer. However, the levels of these markers were not associated with serosal exposure. Although cut-off values at each tumor progression stage could not be determined in the present study, determination of the combined levels of the two markers will facilitate decision making about treatment strategies for far-advanced gastric cancer.

Acknowledgments

This study was supported by a grant from the National Research Foundation of Korea (No. 2012R1A1A043576) and the Catholic Medical Center Research Foundation made in the program year of 2012.

References

1. Sikaroodi M, Galachiantz Y, Baranova A. Tumor markers: the potential of "omics" approach. Curr Mol Med 2010;10:249-257.
2. Seregini E, Ferrari L, Martinetti A, Bombardieri E. Diagnostic and prognostic tumor markers in the gastrointestinal tract. Semin Surg Oncol 2001;20:147-166.
3. Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med 2007;18:175-184.
4. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-856.
5. Meany DL, Sokoll LJ, Chan DW. Early detection of cancer: immunoassays for plasma tumor markers. Expert Opin Med Diagn 2009;3:597-605.
6. Fan B, Xiong B. Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterology 2011;58:239-245.
7. Dilege E, Mihmanli M, Demir U, Ozer K, Bostanci O, Kaya C, et al. Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer. Hepatogastroenterology 2010;57:674-677.
8. Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, et al. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. Anticancer Res 1997;17:2903-2906.
9. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 2014;17:26-33.
10. Leja M, Wex T, Malfertheiner P. Markers for gastric cancer pre-malignant lesions: where do we go? Dig Dis 2012;30:268-276.
11. Basbug M, Arikanoglu Z, Bulbulier N, Cetinkaya Z, Aygen E, Akbulut S, et al. Prognostic value of preoperative serum CEA, CA 19-9 and CA 242 in colorectal cancer. Anticancer Res 2011;31:400-405.
12. Eskelinen M, Pasanen P, Kulju A, Janatuinen E, Miettinen P, Poikolainen E, et al. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer. Anticancer Res 1994;14:1427-1432.
13. Irvine T, Scott M, Clark CI. A small rise in CEA is sensitive for recurrence after surgery for colorectal cancer. Colorectal Dis 2007;9:527-531.
14. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al; NSW Pancreatic Cancer Network. The prognostic
and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012;23:1713-1722.

15. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005;93:740-743.

16. Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N, et al. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer. Pancreas 1994;9:735-740.

17. Chen S, Feng XY, Li YF, Zhao BW, Zhou ZW, Chen YB. The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy. J Surg Oncol 2013;107:641-645.

18. Park SS, Min JS, Lee KJ, Jin SH, Park S, Bang HY, et al. Risk stratification for serosal invasion using preoperative predictors in patients with advanced gastric cancer. J Gastric Cancer 2012;12:149-155.

19. Kang Y, Wang F, Zu H, Yang Z, Xue Y. A new subclassification of pT4 gastric cancers according to the width of serosal invasion. PLoS One 2013;8:e68042.

20. Shim JH, Yoo HM, Lee HH, Kim JG, Jeon HM, Song KY, et al. Use of laparoscopy as an alternative to computed tomography (CT) and positron emission tomography (PET) scans for the detection of recurrence in patients with gastric cancer: a pilot study. Surg Endosc 2011;25:3338-3344.

21. Hur H, Lee HH, Jung H, Song KY, Jeon HM, Park CH. Predicting factors of unexpected peritoneal seeding in locally advanced gastric cancer: indications for staging laparoscopy. J Surg Oncol 2010;102:753-757.